In Vitro and in Vivo Activities of HQQ-3, a New Triazole Antifungal Agent
mice (Center of Laboratory animal, Second Military Medical University, Shanghai, China) weighing 18 to 22 g were used for the present study after an acclimation period of approximately 1 week. They were caged in groups of 10 and given food and water ad libitum.
Antifungal Susceptibility Testing The MICs for yeast were determined by a broth microdilution method based on the NCCLS method outlined in documents M27-T B 19) and M27-A, 20) with slight modifications. [21] [22] [23] RPMI 1640 medium buffered to pH 7.0 with 3-(N-morpholino)-propanesulfonic acid (MOPS) at a final concentration of 0.165 M was used as the culture medium, and the inoculum size was 1.0ϫ10 3 to 5.0ϫ10 3 cells/ml. The microdilution plates inoculated with the fungi were incubated at 30°C. MIC endpoints for Candida spp. were determined after incubation for 24 h, and for C. neoformans, MIC endpoints were determined after incubation for 72 h. These endpoints were defined as the lowest concentration that produced an 80% reduction of growth compared with that of the drug-free growth control. The MICs for filamentous fungi were determined by the broth microdilution method. 23, 24) RPMI 1640 medium buffered to pH 7.0 with MOPS was used as the culture medium. The inoculum was prepared by suspending conidia of filamentous fungi in phosphate-buffered saline containing 0.05% Tween 80. The conidia were counted using a hemocytometer and then diluted into the growth medium to a concentration of 1.0ϫ10 4 conidia/ml. A drug free positive control was included for each isolate. The microdilution plates were incubated in moist chambers at 30°C for 5 d. The MICs were read visually and were defined using a no-growth end point. C. parapsilosis ATCC18062 and C. krusei ATCC19297 were used as quality control organisms, and tested with each assay.
Systemic Infections For C. albicans SC5314, a fungal suspension was prepared with sterile saline. The mice were inoculated with 2.0ϫ10 6 0.5% sodium carboxymethyl cellulose per day. Statistical Analysis The 50% effective doses (ED 50 s) and 95% confidence limits were calculated by the probit method from the survival rates on day 14 for mice infected with C. albicans and C. krusei.
RESULTS

In Vitro Antifungal Activity
In vitro antifungal activity of HQQ-3 against clinically important isolates of yeast and filamentous fungi was compared with those of several azoles and terbinafine. Table 1 shows the MIC 80 s for the yeast strains tested. HQQ-3 showed potent activities against the isolates of C. albicans, C. parapsilosis, C. glabrata, C. tropicalis and C. krusei, with MIC 80 s of 2 mg/ml or less, which were similar to that of ketoconazole and 8 to Ͼ256 times lower than that of fluconazole. Almost all isolates of Candida spp. were resistant to terbinafine (MIC 80 s rang, 4 to Ͼ64 mg/ ml). The MIC 80 s of HQQ-3 for C. neoformans was 0.125 to 2 mg/ml, and its antifungal activity was similar to that of terbinafine but slightly inferior to that of ketoconazole. Table 2 shows the in vitro activities of the drugs tested against the filamentous fungi. MIC 80 s of HQQ-3 against this species were р0.125 to 2 mg/ml. The in vitro activity of HQQ-3 was superior to that of fluconazole and comparable to that of ketoconazole, but HQQ-3 was still less active than terbinafine against them.
Efficacy against Systemic Infections We compared protective effects of HQQ-3 with those of fluconazole against lethal systemic infections in mice caused by C. albicans and C. krusei, and the results are shown in Table 3 . Against infections caused by fluconazole-susceptible C. albicans SC5314, HQQ-3 exhibited a strong efficacy, with an ED 50 of 0.12 mg/ kg, which was superior to that of fluconazole. Against fluconazole-resistant C. albicans 0305279, HQQ-3 was more effective than fluconazole with an ED 50 of 1.9 mg/kg. HQQ-3 also exhibited strong efficacies against C. krusei ATCC-19297, with ED 50 of 1.3 mg/kg, which made it more potent than fluconazole.
DISCUSSION
In the present study, HQQ-3, a new triazole antifungal agent, showed potent in vitro antifungal activities against clinically important fungi. The in vitro antifungal activities of HQQ-3 were superior to those of fluconazole and similar to those of ketoconazole. Recently, the increase in the number of fluconazole-resistant C. albicans isolates has become a clinical problem. 17, 25) In this study, we used two fluconazoleresistant laboratory C. albicans strains, C. albicans SC-5314F50 and ATCC76615F55 (MIC 80 s 64 mg/ml), which were strains developed by co-cultured with increasing concentrations of fluconazole from the sensitive ones (C. albicans sc5314 and ATCC76615). It is known that various mechanisms are responsible for resistance to fluconazole, for example, elevated levels of expression of a multiple drug efflux pump such as MDR1, CDR1, or CDR2. 26) C. albicans #1, #4, #17 came from a single patient, and #1 was fluconazole-susceptible isolate, while #4 and #17 were fluconazoleresistant isolates. #4 was a strain known to upregulate MDR1, and #17 was a stain upregulating CDR1, CDR2 and MDR1. C. albicans FH1 and FH5 also came from a single patient, and FH5 was a stain upregulating CDR1 and CDR2. We also used some clinically fluconazole-resistant isolates. These results indicate that HQQ-3 inhibits the growth of not only susceptible but also resistant Candida spp., C. neoformans and filamentous fungi.
As for the in vivo activity, HQQ-3 exhibited good efficacies against murine systemic infections caused by fluconazole-susceptible C. albicans, fluconazole-resistant C. albicans and C. krusei and was more potent than fluconazole under the experimental conditions.
Toxicity of HQQ-3 in animals was weaker than fluconazole (data not shown).
In conclusion, excellent in vitro and in vivo activities of HQQ-3 against these fungi suggest that HQQ-3 may be a potential antifungal drug candidate for the treatment of various clinical forms of various systemic candidiasis. 
